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Abstract
Background: The minimum clinically important difference (MCID) is used to interpret the clinical relevance of
results reported by trials and meta-analyses as well as to plan sample sizes in new studies. However, there is a lack
of consensus about the size of MCID in acute pain, which is a core symptom affecting patients across many clinical
conditions.
Methods: We identified and systematically reviewed empirical studies of MCID in acute pain. We searched PubMed,
EMBASE and Cochrane Library, and included prospective studies determining MCID using a patient-reported anchor
and a one-dimensional pain scale (e.g. 100 mm visual analogue scale). We summarised results and explored reasons
for heterogeneity applying meta-regression, subgroup analyses and individual patient data meta-analyses.
Results: We included 37 studies (8479 patients). Thirty-five studies used a mean change approach, i.e. MCID was
assessed as the mean difference in pain score among patients who reported a minimum degree of improvement,
while seven studies used a threshold approach, i.e. MCID was assessed as the threshold in pain reduction associated
with the best accuracy (sensitivity and specificity) for identifying improved patients. Meta-analyses found considerable
heterogeneity between studies (absolute MCID: I2 = 93%, relative MCID: I2 = 75%) and results were therefore presented
qualitatively, while analyses focused on exploring reasons for heterogeneity. The reported absolute MCID values ranged
widely from 8 to 40 mm (standardised to a 100 mm scale) and the relative MCID values from 13% to 85%. From
analyses of individual patient data (seven studies, 918 patients), we found baseline pain strongly associated with
absolute, but not relative, MCID as patients with higher baseline pain needed larger pain reduction to perceive
relief. Subgroup analyses showed that the definition of improved patients (one or several categories improvement or
meaningful change) and the design of studies (single or multiple measurements) also influenced MCID values.
Conclusions: The MCID in acute pain varied greatly between studies and was influenced by baseline pain, definitions
of improved patients and study design. MCID is context-specific and potentially misguiding if determined, applied or
interpreted inappropriately. Explicit and conscientious reflections on the choice of a reference value are required when
using MCID to classify research results as clinically important or trivial.
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Background
It can be challenging to decide whether a modest effect
in a randomised clinical trial, or a meta-analysis of
several such trials, is clinically relevant. Statistical tests
inform on the probability of a result being a chance find-
ing; however, they convey no information on whether a
given effect will be experienced as important by patients.
The degree of pain reduction that is considered clinically
relevant has an impact on which analgesic interventions
are regarded clinically useful. This interpretation prob-
lem for clinical relevance has been at the core of debates
of the importance of several types of interventions
intended for reducing acute pain, for example, paraceta-
mol [1–3], non-steroidal anti-inflammatory drugs [4, 5],
morphine or synthetic opiates [6], corticosteroids [7],
muscle relaxants [4], laser therapy [8], transcranial direct
current stimulation [9], EMLA cream [10], and acupunc-
ture [11]. A related challenge involves the calculation of
sample sizes for clinical trials, where researchers need to
know the smallest clinically important effect that the trial
should not miss to be able to determine an adequate
sample size.
Jaeschke et al. [12] characterised the concept of mini-
mum clinically relevant difference in 1989 as “the smallest
difference in score in the domain of interest which partici-
pants perceive as beneficial and which would mandate, in
the absence of troublesome side effects and costs, a change
in the patient’s management”. The strength of the concept
is that it defines a relevant effect size based on clinical
considerations and not only statistical significance [13, 14].
It has subsequently been supplemented by a related
concept – the substantial (and not only minimum) clinic-
ally relevant difference [15].
The minimum clinically important difference (MCID)
is sometimes chosen on the basis of expert consensus
judgement [16], statistical models [17] or objective
criteria [18]. However, in acute pain, it seems reasonable
to anchor clinical relevance to the patients’ experience.
This approach is in accordance with the increasing
awareness of the relevance of patient-reported outcomes
in clinical research [19]. Several such empirical studies
have been conducted to determine the MCID in acute
pain, but they differ with regard to methodology, clinical
condition and findings, and have not yet been systemati-
cally reviewed. Since acute pain is a core symptom in
healthcare, an assessment of the MCID and a clarifica-
tion of the causes for its variation will have broad inter-
est. It has been suggested that baseline pain influences
absolute values of MCID, but study reports have been
conflicting [20, 21], and it remains unclear which other
clinical or methodological factors are of importance.
We therefore decided to systematically review empirical
studies of the MCID in acute pain relief and to examine
possible causes for variation between study results,
especially their likely dependency on baseline pain levels.
We also reviewed studies of the substantial clinically im-
portant difference in acute pain relief as well as clinically
important differences for worsening of pain.
Methods
Eligibility criteria
We included prospective studies of patients with acute
pain, regardless of age, clinical condition, and interven-
tion, in which pain intensity was assessed on a one-
dimensional scale, e.g. a 100 mm visual analogue scale
(VAS) or a 0–10 point numerical rating scale (NRS), and
in which the MCID was determined using an anchor-
based method using patients’ perception of change to
determine clinical importance. Pain was considered acute
when its duration was less than 1 month or, if duration
was not indicated, when it was described as such in a
study report.
Studies were excluded if they were not clinical (i.e.
used healthy volunteers) or determined the MCID from
objective criteria (e.g. return to work), the distribution
of data (e.g. the minimum detectable difference) or
expert consensus.
A typical eligible study would ask patients to score
their pain intensity, e.g. using a VAS, at baseline and
follow-up. At follow-up, patients were also asked to
categorise their change in pain intensity using response
options such as ‘no change’, ‘a little better’/‘somewhat
better’, and ‘a lot better’/‘much better’. The MCID was
then determined from the change in scores on the pain
scale among patients having categorised their change as
‘a little better’ (or a similar expression indicating a
minimum clinically important improvement).
We included studies with two types of analytical ap-
proaches (1) the ‘mean change approach’, i.e. the mean
difference in pain scores among patients who reported a
minimum degree of pain relief [22]; or (2) the ‘threshold
approach’, i.e. the threshold value for pain score change
which most accurately (yielding best sensitivity and
specificity) identified patients experiencing relevant pain
relief in analogy with a diagnostic test where the gold
standard is patients’ perception of change [23].
Search strategy
We searched PubMed, EMBASE and Cochrane Library
until August 2016 with no language restrictions. The
core search string was: (minimal OR minimally OR
minimum OR ‘clinically significant’ OR ‘clinically import-
ant’ OR ‘clinically meaningful’ OR ‘clinically relevant’)
AND (difference OR change OR relief OR reduction)
AND (‘pain measurement*’ OR ‘visual analog scale’ OR
‘numeric rating scale’) AND (pain) with variations
according to the specific database (Appendix 1). The
reference lists of all included studies and relevant
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review papers were read systematically to identify fur-
ther studies.
Screening of titles and abstracts to determine the eligi-
bility of studies was done by the primary author (MFO),
while the selected full-text records were examined by two
researchers independently (MFO and either EB, NEL, BT,
or MDH). Any disagreement was solved by discussion.
Data extraction and retrieval
Data extraction was conducted by two researchers inde-
pendently (MFO and EB, BT, or NEL) using pretested data
extraction forms generated in EpiData (EpiData Associ-
ation, Odense, Denmark). Any disagreements were solved
by discussion.
For each study, we extracted descriptive data including
publication year, study design, setting, clinical condition,
type of intervention, sampling method, sample size, and
definition of patients with relevant change (see Appendix
2 for complete list). For studies using a mean change ap-
proach, we extracted the following outcome data: the
MCID for pain relief (absolute values in mm or points and
relative value in percent change from baseline) and
for pain worsening (absolute and relative values), as well
as the substantial clinically important difference for relief
and worsening of pain (absolute and relative values). We
extracted MCIDs as the mean change in pain score among
patients who indicated a one-category improvement (e.g.
‘a little better’). If unavailable, we extracted the mean
change among patients who were minimally improved by
authors’ definition (e.g. some authors defined minimum
important change as the mean change in pain score
among patients with either a one- or two-category im-
provement). Similarly, we extracted the substantial clin-
ically important differences as the mean change among
patients with a two-category improvement or used the
authors’ definition. We extracted the point estimate of
outcomes with their corresponding standard error or, if
unavailable, other measures of variation such as stand-
ard deviation or 95% confidence interval.
For studies using a threshold approach, we extracted in-
formation about definition of responders (i.e. patients with
relevant change) and non-responders and the cut-off point
with its corresponding sensitivity (i.e. percentage of res-
ponders correctly classified as such) and specificity (i.e.
percentage of non-responders correctly classified as such).
If studies reported pain scores from several concurrent
pain assessments (e.g. back pain and leg pain), we ex-
tracted the assessment where more data were available or,
if no difference found, we randomly selected which to
extract. All scales were standardised to a 0–100 mm scale.
When studies reported pain assessments based on both
VAS and NRS, we used the assessment based on VAS.
If the primary outcome or other key variables were
unclear or incompletely reported from a study, we
contacted the corresponding author. In cases where
authors provided individual patient data, we first
checked whether we could replicate a main result of the
published paper. We then calculated estimates of abso-
lute and relative MCIDs and their corresponding
standard error.
For each study, we assessed risk of attrition bias (studies
were considered low risk when attrition < 10%) and risk of
non-representative study sample (studies were consid-
ered low risk if using consecutive or random sampling).
Data synthesis and analysis
For each study, we extracted or calculated the MCID for
pain relief (absolute and relative change), and noted
results of any study-based exploration of causes for
variation, e.g. baseline pain.
We then summarised results qualitatively as there was
considerable clinical and methodological variation between
studies and heterogeneity in their results. To provide an
overview, we first reported the range of results for all
studies and then the range and median results with inter-
quartile ranges (IQR) of studies according to analytical
strategy (mean change or threshold approach). To facilitate
exploration of reasons for heterogeneity, we then
pooled results of studies using mean change approach
with inverse-variance meta-analysis using random ef-
fects models. We studied the association with baseline
pain scores in three different analyses. First, we ex-
plored the impact of the average population baseline
pain in a mixed-effects meta-regression (acknowledging
the limitations of aggregated data-level analysis [24]).
Second, we pooled individual patient data to estimate
the MCID (absolute and relative changes) using a two-
stage individual participant data meta-analysis. In these
models, MCIDs were first estimated in each individual
study using a mixed model based on all repeated mea-
surements and participant specific random effects to
capture the serial correlation within each participant.
Results were then pooled using random-effects inverse-
variance meta-analysis. Third, we used the same model
to derive outcomes measured at different time points in
studies with multiple measurements per patients (i.e. the
use of a ‘moving baseline’).
We furthermore used subgroup analyses to explore
whether between-study variation was explained by differ-
ences in other clinical and methodological factors in-
cluding clinical condition, type of pain scale (VAS vs.
NRS), directionality of global transition scale (one-sided
vs. two-sided scale), definition of minimum clinically
important change (one category vs. several categories
improvement vs. distinction between meaningful and
non-meaningful change), number of pain assessments
per patients (single vs. multiple assessments adjusted for
correlation vs. multiple unadjusted assessments), risk of
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attrition bias (low vs. high or unclear) and risk of non-
representative sample (low vs. high or unclear).
Finally, we used the same analysis strategy for the
substantial clinically important difference for pain relief
(absolute and relative change) and the minimum and
substantial clinically important differences for worsening
of pain (absolute and relative change).
All data analyses were done using Stata/IC version 13.
Results
Study selection
We screened 1553 database records and read 273 full-
text publications (Fig. 1). We excluded 237 publications,
mostly because they included patients with chronic pain
(n = 63) or multi-dimensional pain scales (n = 53). Thus,
we included 36 publications [21, 25–59] reporting 37
studies (8479 patients).
Characteristics of included studies
The majority of studies were based in emergency depart-
ments and included a mix of patients with acute pain of both
traumatic and non-traumatic origin (10 studies) or unspeci-
fied pain (7 studies). Additional studies included patients
with post-operative pain, cancer-related pain, sickle cell cri-
sis, rheumatic pain, abdominal pain, low back pain, or head-
ache (Tables 1 and 2). All studies were published in English.
Twenty studies assessed pain using a 100 mm VAS (or
the similar Color Analog Scale), and 12 studies used an
11-point NRS (0–10), while five studies used both scales. In
32 studies, patients compared their current pain intensity
with pain at their previous assessment, while they were
asked to assess the effect of their treatment in five studies
[25, 49, 58]. Transition scales were either two-sided (29
studies) with 3–15 response categories for both improve-
ment and deterioration, or one-sided (8 studies) with five
response categories addressing only improvement.
Fig. 1 Flow chart of study identification. MCID = Minimal Clinically Important Difference, aAdditional records identified through “related papers”
function in databases and reference lists of screened papers, bTwo records include both acute and chronic pain studies, cIncludes studies in
which MCID was not based on subjective patient-reported assessment of pain relief
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For studies using the mean change approach, the ma-
jority defined the minimum clinically important im-
provement as a one-category improvement on the
transition scale (31 studies). The response categories
were similar with wordings such as ‘a little less pain’, ‘a
bit better’, ‘slightly improved’, or ‘slight relief ’. In four
studies, the MCID was defined as the mean change in
pain score among patients with a one- or two-category
improvement, thereby combing patients answering
‘some relief ’ and ‘partial relief ’ [55], or ‘much improved’
and ‘best ever’ [49–51]. Finally, two studies differentiated
between non-important and important change, using the
categories ‘inadequate relief ’ and ‘moderate relief ’ in one
study [40], and ‘poor’ and ‘less good’ efficiency of treat-
ment in another [25] (Table 1). Studies using the thresh-
old approach had large variation in transition scales and
definitions of responders versus non-responders; patients
were regarded as importantly improved if they indicated a
one-category relief in two studies [41, 57], while they
needed a five-category improvement in another [58]
(Table 2).
Pain intensity was assessed at baseline and a single
follow-up measurement in 14 studies, while it was
assessed at multiple (from 2 to 16) follow-ups with
intervals between 10 and 45 minutes in 23 studies. The
latter group then derived their outcome as the sum-
marised mean difference in pain score from the pa-
tients’ previous pain assessment when they reported
minimum relief (i.e. a series of ‘moving baselines’). In
eight of these studies, the P values of analyses were
adjusted for correlation between estimates, for example,
with Generalised Estimation Equation, while the
remaining studies either made no adjustment or did
not report this. Access to individual patient data in-
creased the number of studies with adjusted estimates
to 11.
In 10 studies, the MCID was defined as a numeric
change for all patients with minimum change, regardless
of whether pain had improved or worsened. After con-
tacting authors, separate estimates for pain relief were
available from eight of these.
MCID regardless of analytical approach
Standardised to a 100-mm scale, the absolute MCID in
30 studies ranged from 8 to 40 mm, and the relative
difference in 15 studies ranged from 13% to 85%.
MCIDs in studies using the mean change approach
The determination of the MCID was based on a mean
change approach in 35 studies, of which 30 (6598
patients) were included in our analyses and five were
disregarded (see below). Twenty-nine studies (6517 pa-
tients) reported absolute values ranging from 8 to 40 mm,
with a median of 17 mm (IQR 14–23 mm) (Fig. 2a). Only
nine of the 30 studies reported relative MCIDs, but access
to individual patient data made relative values available
from 14 studies (1617 patients) ranging from 13% to 85%,
with a median of 23% (IQR 18–36%) (Fig. 2b).
Fig. 2 a Range of absolute minimal clinically important differences
in acute pain assessed by the mean change approach* (29 studies,
6517 patients). *MCID assessed as the mean change in pain score
among patients with minimal improvement of pain, MCID = Minimal
Clinically Important Difference (mm reduction on a 100 mm scale),
Studies where standard error (or data for obtaining this) was unavailable
are presented as point estimates without 95% CI (NA = not applicable).
b Range of relative minimal clinically important differences in acute pain
assessed by the mean change approach* (14 studies, 1617 patients).
*MCID assessed as the mean change in pain score among patients with
minimal improvement of pain, MCID = Minimal Clinically Important
Difference (% reduction from baseline), Studies where standard
error (or data for obtaining this) was unavailable are presented as
point estimates without 95% CI (NA = not applicable)
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For data syntheses, we did not include results from five
of the 35 studies (1567 patients) as they did not differentiate
between pain relief and pain worsening [21, 48], because
median (and not mean) differences in pain were reported
[26, 33], or because outcomes were reported for subgroups
and no overall estimate could be derived [36]. The range of
MCID in these studies was comparable to the included
studies: 10–19 mm. An additional six studies (493 patients)
were not included in meta-analysis since information about
standard error of estimates was unavailable [40, 49, 53, 54].
The results from these studies ranged from 11 to 40 mm.
We had data usable for meta-analyses from 23 studies
(6024 patients) reporting absolute values and 11 studies
(1397 patients) reporting relative values. Meta-analyses of
both the absolute and relative values showed considerable
heterogeneity: I2 = 93%, P < 0.001 and I2 = 75%, P < 0.001
(Table 3). We present the meta-analyses for completeness
and as a basis for exploring reasons for the heterogeneity,
but stress that medians and interquartile ranges are more
appropriate descriptors of the results.
MCID in studies using the threshold approach
Seven of the 37 included studies (2602 patients) deter-
mined clinically important differences as a threshold
to differentiate between patients with or without rele-
vant pain relief. Absolute thresholds ranged from 10 to
35 mm in six studies (2331 patients) with a median of
10 mm, and the relative threshold ranged from 15% to
50% in four studies (534 patients) (Table 3). In one
additional study [58], patients were defined as responders if
they indicated at least a five-category improvement. The
corresponding clinically important differences were thus
higher (34 to 63 mm depending on baseline pain) than in
studies where patients only needed a one- [41, 57], two-
[49], or three-category improvement [25], respectively, to
be defined as responders (Table 2).
Table 3 Clinically important differences in acute pain
Analysis of mediansa Analysis of pooled average
Clinically important difference Range Number of studies
(patientsb)
MCID median
(IQR)
Number of studies
(patientsb)
MCID pooled average
(95% CI), I2 c
Minimum clinically important difference for pain relief
Absolute change, mm
Mean change approach 8 to 40 29 (6517) 17 (14 to 23) 23 (6024) 17 (15 to 19), 93%
Threshold approach 10 to 35 6 (2331) 10 (10 to 10) NA NA
Relative change, %
Mean change approach 13 to 85 14 (1617) 23 (18 to 36) 11 (1397) 22 (19 to 26), 75%
Threshold approach 15 to 50 4 (534) 50 (33 to 50) NA NA
Substantial clinically important difference for pain relief
Absolute change, mm
Mean change approach 18 to 54 23 (6114) 32 (24 to 38) 21 (5891) 32 (27 to 38), 97%
Relative change, %
Mean change approach 36 to 78 11 (1397) 57 (45 to 65) 11 (1397) 57 (47 to 67), 94%
Minimum clinically important difference for pain worsening
Absolute change, mm
Mean change approach −21 to –8 18 (3822) −11 (–13 to –10) 16 (3644) −12 (–14 to –11), 62%
Relative change, %
Mean change approach −89 to –17 7 (918) −44 (–90 to –16) 7 (918) −35 (–47 to –23), 67%
Substantial clinically important difference for pain worsening
Absolute change, mm
Mean change approach −66 to 0 16 (3663) −21 (–28 to –16) 14 (3464) −24 (–29 to –18), 71%
Relative change, %
Mean change approach −292 to –18 7 (918) −83 (–292 to –18) 7 (918) −34 (–49 to –19), 20%
MCID minimum clinically important difference (mm or % reduction on a 100 mm scale), SCID substantial clinically important difference (mm or % reduction on a
100 mm scale), IQR inter-quartile range, NA not applicable
aThe median is based on studies included in the pooled average as well as studies with unavailable standard errors
bTotal number of patients in the included studies
cI2 is the percentage of the variability in results that is due to heterogeneity rather than sampling error (chance); I2 of 0% to 40% might not be important, 30% to
60% may represent moderate heterogeneity, 50% to 90% may represent substantial heterogeneity, and 75% to 100% represents considerable heterogeneity
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Impact of baseline pain scores on the MCID
Eleven studies had assessed the possible influence of
baseline pain on minimum clinically improvement
(Appendix 3). Of nine studies assessing absolute change,
seven reported an association [31, 33, 36, 43, 58, 59]. The
two remaining studies found no association, but these
were disregarded since they determined the MCID
without differentiating between pain relief and pain
worsening [21, 45]. Six studies assessed the association
between baseline pain and relative change and either
found the association to be non-significant or found it to
be weaker than for absolute change.
Based on meta-regression, we found no association
between baseline pain and either absolute (20 studies, P =
0.70) nor relative (9 studies, P = 0.83) estimates of MCIDs.
However, based on individual patient data meta-
analysis from seven studies (918 patients), we found a
strong association between baseline pain and absolute
MCID, showing that patients with higher baseline pain
need larger pain reduction to reach a minimum clinically
relevant difference compared to patients with lower
baseline pain. For each 10 mm increase in baseline pain,
MCID increased by 3.1 mm (95% confidence interval,
2.8–3.5 mm, P < 0.001, I2 = 0%). Thus, for patients with
initial pain levels < 40, 40–70, and > 70 mm, the MCIDs
were 6 (4–8) mm, 13 (11–14) mm, and 21 (20–23) mm,
respectively (Fig. 3). The corresponding relative esti-
mates of MCIDs did not differ significantly: 17 (4–30) %,
23 (20–25) %, and 24 (22–26) %, respectively. In con-
trast, we found that patients with more severe pain
perceived worsening of their status with smaller in-
creases of pain intensity: the absolute MCID was
2.3 mm less for each 10 mm increase in baseline pain
(1.4–3.0, P < 0.001, I2 = 67%).
From individual patient data, we also found that the
MCID decreased with increasing time from baseline,
from 17 (12 to 21) mm at 30 minutes to 11 (8 to 14) mm
at 120 minutes. However, patients’ pain level declined ac-
cordingly during the multiple follow-ups and estimates
expressed as a relative change from the previous assess-
ment therefore did not decline.
Impact of other clinical and methodological factors
Other causes for variation in the MCID were addressed
in 10 studies. These included sex [33, 35, 36, 44–48, 51,
54, 57, 59], age [33, 35, 36, 44–46, 48, 51, 54, 57, 59],
education level [35, 48, 51, 54], ethnicity [54, 57], pri-
mary language (English or Spanish) [57], and religion
[54], as well as cause (traumatic or non-traumatic)
[44–48, 57], duration [35] and location [35] of pain.
None of the studies found associations except for one
[48], which reported higher MCIDs for men compared
to women and for non-traumatic pain compared to
traumatic pain. However, these analyses were not ad-
justed for differences in baseline pain.
The MCIDs of subgroups are presented as medians
and pooled averages, respectively (Table 4). For most
clinical and methodological factors, the number of
studies in each subgroup was too small to ensure detec-
tion of relevant differences between them. Nevertheless,
although only few studies defined the MCID as the
mean pain reduction among patients with several cat-
egories of improvement, or patients with ‘meaningful’
(and not just ‘minimum’) change, it was clear that these
studies found higher MCIDs (medians 25 (IQR 23–29)
and 34 (IQR 27–40), respectively) than studies where it was
Fig. 3 Minimum clinically important difference by baseline pain
(individual patient data from 7 studies, 918 patients). MCID assessed
as the mean change in pain score among patients with minimal
improvement of pain, MCID = Minimal Clinically Important Difference
(mm reduction on a 100 mm scale). Forest plot of mean pain difference
in 723 episodes where patients reported pain to be “a little better” in 7
studies including a total of 918 patients
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defined as the mean pain reduction among patients with a
one-category improvement (median 16 (IQR 13–21)). It was
also clear that the MCID was higher when based on a single
assessment involving one fixed baseline value (median 25
(IQR 23–29)), than when summarised from multiple assess-
ments with the previous assessment applied as a ‘moving
baseline’ (medians 15 (IQR 13–16) and 16 (IQR 10–21),
respectively). Subgroups of studies among patients with
various clinical conditions were underpowered to detect rele-
vant differences. The comparison of one- and two-sided
transition scales was also underpowered, but the difference in
scales did not seem to affect study results, while the compari-
son of VAS and NRS included enough studies to conclude
that type of pain scale did not influence the MCID. Finally,
we did not find differences in outcomes relating to the risk of
attrition bias or risk of non-representative samples.
Supplementary outcomes
The supplementary outcomes for pain relief and worsening
were only reported from studies using the mean change
Table 4 Subgroup analyses of absolute minimum clinically important differences (MCIDs) for pain relief
Subgroup Analysis of medians Analysis of pooled average
Range, mm Number of studiesa
(patientsb)
MCID Median,
mm (IQR)
Number of studies
(patientsb)
MCID pooled average,
mm (95% CI), I2 c
All studies 8–40 29 (6517) 17 (14–23) 23 (6024) 17 (15–19), 93%
Clinical conditions
Post-operation paind 9–29 7 (731) 18 (10–25) 3 (361) 11 (8–14), 42%
Trauma 16–20 2 (125) 18 (16–20) 2 (125) 18 (15–22), 11%
Abdominal pain 18–25 2 (407) 21 (18–25) 2 (407) 21 (15–28), 91%
Mixed patients at ED 8–24 7 (2418) 15 (11–21) 6 (2345) 16 (12–20), 90%
Othere 10–40 5 (1980) 27 (23–34) 4 (1930) 22 (15–29), 92%
Unspecified 13–21 6 (856) 16 (14–16) 6 (856) 16 (14–18), 72%
Definition of MCID
One category improvement 8–34 24 (4504) 16 (13–21) 22 (4281) 16 (14–18), 91%
Several categories improvement 23–29 3 (220) 25 (23–29) NA NA
Meaningful change 27–40 2 (1793) 34 (27–40) 1 (1743) 27 (25–29), NA
Directionality of transition scale
One-sided 9–40 5 (538) 18 (13–21) 3 (383) 15 (8–21), 93%
Two-sided 8–25 19 (3962) 16 (13–20) 18 (3844) 16 (14–19), 91%
Pain scale
Visual Analogue Scale 8–40 17 (3232) 17 (13–25) 15 (3109) 16 (13–19), 91%
Numeric Rating Scale 10–23 7 (1268) 15 (14–21) 6 (1118) 16 (14–19), 91%
Measurements per patient
Single 18–40 4 (461) 25 (23–29) 4 (2058) 22 (19–25), 0%
Multiple
With adjustment 10–18 9 (1104) 15 (13–16) 8 (1031) 15 (13–16), 34%
Without Adjustment/unclear 8–25 11 (2935) 16 (10–21) 11 (2935) 16 (13–20), 95%
Risk of attrition bias
Low 8–40 8 (1249) 19 (15–25) 8 (1249) 16 (14–18), 81%
High or unclear 9–25 16 (3251) 16 (12–19) 13 (2978) 16 (13–19), 93%
Risk of non-representative sampling
Low 8–25 6 (1187) 16 (10–21) 6 (1187) 16 (11–21), 96%
High or unclear 9–40 18 (3313) 18 (14–24) 15 (3040) 16 (14–18), 87%
IQR inter-quartile range, ED Emergency department, NA not applicable
aThe median is based on studies included in the pooled average as well as studies with unavailable standard errors
bTotal number of patients in studies
cI2 is the percentage of the variability in results that is due to heterogeneity rather than sampling error (chance); I2 of 0% to 40% might not be important, 30% to
60% may represent moderate heterogeneity, 50% to 90% may represent substantial heterogeneity, and 75% to 100% represents considerable heterogeneity
dIncludes knee surgery, laparotomy, third molar extraction and mixed surgery (e.g. spinal fusion and splenectomy)
eIncludes headache, low back pain, sickle cell crisis, rheumatic condition, and pain flare after external beam radiotherapy for bone metastases
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approach (Table 3). The results showed similarly high hete-
rogeneity. The substantial clinically important difference
for pain relief ranged from 18 to 54 mm (23 studies), while
minimum and substantial clinically important differences
for worsening of pain ranged from 8 to 21 mm increase
(18 studies) and from 0 to 66 mm increase (16 studies),
respectively.
Discussion
We included 37 studies (8479 patients) assessing the
MCID in acute pain, of which 35 used the mean
change approach and seven used the threshold ap-
proach. Meta-analyses found considerable heterogen-
eity between studies and, consequently, no single
value of minimum clinical important difference could
be meaningfully determined. Study results ranged
widely both when they were reported as absolute
change (from 8 to 40 mm) and as relative change
from baseline (from 13 to 85%). The median of study
results based on the mean change approach was 17
(IQR 14 to 23) mm and 23 (IQR 18 to 36) % for ab-
solute and relative values, respectively. Reasons for
heterogeneity were explored and baseline pain was
identified as a cause of variation in absolute, but not
relative, outcomes. In addition, the definition of mini-
mum clinically important change and the use of mul-
tiple assessments per patient influenced study results.
High heterogeneity was also found for assessments of
substantial clinically important difference as well as
for worsening of pain.
Strengths and limitations
To our knowledge, this is the first systematic review
of MCIDs in acute pain. We identified 37 studies in-
volving over 8000 patients and a broad range of
clinical conditions, study approaches and pain scales.
We gained access to unpublished data from 10 stud-
ies, including individual patient data from seven stud-
ies (918 patients). This ensured high data quality and
uniform analysis, and enabled an adequate assessment
of the association with baseline pain avoiding the risk
of ecological fallacy [24] inherent to aggregated study-
level data. The median results of studies providing
individual patient data was comparable with the
remaining studies and we have no reason to believe
these studies were not representative. Association
with baseline pain has been reported from individual
studies [31, 33, 36, 43, 57–59], but the present review
is the first comprehensive assessment of the impact
of baseline pain across studies. In addition, we identi-
fied variation in study designs (single or multiple as-
sessments) and definitions of patients with minimum
relief as factors influencing the MCID.
However, we were not able to fully explain the large
heterogeneity among studies. We found no effects of
pain scale, but for the comparison of clinical condi-
tions and directionality of transition scale, subgroups
involved too few studies to ensure detection of all
relevant associations. In addition, our ability to assess
clinical condition was limited by the fact that many
studies included a mixed patient group and we did
not have access to individual patient diagnoses. Simi-
larly, the studies included a variety of analgesia and
other treatments which did not allow an assessment
of potential impact of interventions. Regarding the
risk of attrition bias and non-representative sampling,
the majority of studies were categorised as unclear
and potential impact could therefore not be assessed.
Most importantly, acknowledging the association with
baseline pain, it would have been more accurate to
base subgroup analyses on relative outcomes, but the
data available only allowed comparison of absolute
outcomes. We could not assess impact of various de-
scription of pain (e.g. “intensity”) or the follow-up
time between measurements since there was not
enough variation between studies. Furthermore, the
available data did not allow an assessment of the po-
tential influence of pre-existing pain level (e.g. if pa-
tients are affected by chronic pain in addition to their
current episode of acute pain), pre-existing use of
pain relief or the psychological state of patients, since
this was not reported by any of the studies. Finally,
we cannot dismiss the risk of recall bias in studies
where patients simultaneously assess their pain sta-
tus and perceived change [60]. Differences in base-
line pain or other methodological or clinical factors
may influence subgroup analyses of study-level data.
Thus, better access to individual patient data would
greatly improve the chances of identifying causes of
heterogeneity.
Other studies
Only few systematic reviews of the minimum clinically
relevant change have been published despite a vast num-
ber of primary studies. Stauffer [20] and Erdogan [61]
reviewed studies of minimum clinically relevant change
in pain scales used for chronic rheumatologic condi-
tions, but we have not identified any systematic reviews
focusing on acute pain.
The problem of variability in results of studies of
minimum clinically relevant change has previously
been addressed primarily when attempting to recon-
cile dissimilar results from different approaches, e.g.
anchor-based and distribution-based studies [62]. Our
study demonstrates considerable unexplained variation
also within anchor-based approaches. In line with our
findings, Terwee [63] found variability between results
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of five studies of minimum clinically important
change on the Western Ontario and McMaster Uni-
versity pain subscale for osteoarthritis. In a systematic
review of the minimum clinical important difference
in chronic pain, we have found similar issues of high
study variability (manuscript in preparation).
Mechanisms and perspectives
We included studies with a patient-reported anchor.
While some find that using a patient-reported criterion
as an anchor for a patient-reported score is circular and
basically flawed [64], we would argue that pain intensity
is essentially a subjective experience best expressed by
and anchored to those experiencing it. Other observer-
based anchors may be used when the outcome of inter-
est is return to work or daily level of activity [65]. The
varying content of the patient-reported anchors is,
however, problematic. The applied transition scales
were either one- or two-sided, allowing patients to re-
port their degree of change (or only relief ) by choosing
between anywhere from three to 15 response categor-
ies. The majority of studies then determined the MCID
as a mean change in pain score among everyone report-
ing a one-category pain relief. However, this value does
not apply to all individuals in the group, since their dif-
ferences in pain are distributed around the mean [14].
In contrast, MCIDs expressed as threshold values are
derived with the intention of obtaining the best possible
discrimination between patients with and without
relevant relief. The frequency of false-positive and
false-negative results may be reduced but is not elimi-
nated by this approach. Therefore, caution is always
merited when bringing an overall estimate of important
change to the level of interpretation for an individual
patient [66, 67].
The studies we included varied considerably both in
methods and analytical approaches. As would be ex-
pected, differences in the definition of patients with
minimum important change impacted study results. We
also found that the use of multiple measurements per
patient resulted in lower outcomes. This corresponded
with the finding that outcomes decreased during several
follow-ups as patients’ pain declined over time. Further-
more, one in four of the reviewed studies did not differen-
tiate between minimum relief and minimum worsening of
pain in their original study reports. The practice of com-
bining groups with minimum change, regardless of its
direction, is sometimes based on a seemingly similar
distribution of data in the two groups [44]. However,
although they may be similar at one point, the MCID for
pain relief and worsening will change in opposite direc-
tions with variations of baseline pain (since patients with
higher baseline pain require larger pain reduction to
perceive relief, but smaller increase to perceive worsening
of their condition).
The association between MCID and baseline pain
may to some extent be explained by ‘regression towards
the mean’ as patients are likely to score closer to the
mean if their initial scores were more extreme because
of chance [68]. However, it is also very plausible that
patients with higher pain require greater decrease to
perceive relief. Relative changes are therefore more
stable indicators of clinically important differences, al-
though they lack interval scale properties at the scale
extremes, e.g. when baseline values are close to zero
and small degrees of pain change result in very large
relative changes [69]. From this review, however, it is
clear that the advantage of relative values is largely
overlooked, since only 10 of 37 studies (27%) reported
relative change.
This review included studies that determined MCID
from an anchor-based method using patients’ percep-
tion of change to determine clinical importance. Al-
though this is the most common approach, it is just
one among a wide range of alternative methods.
Revicki noted that retrospective self-reports of pain
relief tend to correlate more strongly with the end-
level of pain than the start level, implying that the
current status matters to patients more than the de-
gree of improvement [70]. This has led to the devel-
opment of the concept of ‘patient acceptable
symptom state’, defined as the level of symptoms
which patients feel is acceptable [71, 72]. Patient ac-
ceptable symptom state corresponds with the domin-
ant aim of clinical patient care to reduce pain to an
acceptable level [73] and could be a strong candidate
for an alternative to MCID. Other promising ap-
proaches have integrated intervention costs and side
effects [74–77].
It is likely that the challenges of MCID, apparent
for acute pain, may not be isolated to that specific re-
search area. Acute pain stands out because of the
many studies that have been conducted, reflecting the
status of acute pain as a core symptom in clinical
practice. Our study can thus be seen as a model for a
more general challenge with empirical assessments of
the MCID.
The methodological challenges embedded in the
empirical assessment of MCID are of such an extent
that merits caution for its use and interpretation. It is
clearly inappropriate to use and interpret MCID as a
kind of clinical scale constant – a characteristic which,
once empirically determined, is universally valid. This is,
however, often the practice seen [78]. Nevertheless, there
is a strong and reasonable demand for a structured
approach for evaluating whether effects of interventions
are clinically meaningful to patients.
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Implications
The choice of a reference value has large consequences
for the number of patients needed in a trial, e.g. four times
as many patients will be included, if researchers accept a
MCID value of 12 mm as compared to 24 mm. Further,
the conclusion about the clinical relevance of a trial result
is often based on whether a mean difference exceeds a
chosen reference value, but with the large span of MCIDs
available in the literature, it is highly problematic to ran-
domly pick one or a few single assessments for guidance.
The considerable variation means that it is necessary to
conscientiously and explicitly reflect on the span of results
in relation to context-specific clinical and methodological
factors, as presented in this review, with a particular focus
of the baseline pain of patients, whether repeated mea-
surements were used, and how minimum relief was de-
fined. A starting point for such an exercise by individual
clinicians or researchers, or by consensus building com-
mittees, could very well be our overview of studies and
their results.
In future studies there is a clear need for uniform
guidelines for standardised conduct, analyses and
reporting of the MCID, especially for how transition
scales and questions are structured and how data are
analysed. We strongly encourage using values relative
to baseline pain – also for multiple measurements
where the patient’s last assessment should be applied
as a ‘moving baseline’, standardising the definition of
relevant pain relief, and distinguishing clearly between
improvement and worsening of pain. In addition, since
the influence of clinical and methodological factors
is difficult to identify from aggregated data, we
encourage improved access to individual patient
data to enable further exploration of the causes of
heterogeneity.
Conclusion
The MCID in acute pain varied greatly between stud-
ies. Absolute MCID ranged from 8 to 40 mm in 29
studies, and relative values ranged from 13% to 85%
in 14 studies. Baseline pain was strongly associated
with absolute, but not relative, values and variation in
definitions of minimum relief and study designs influ-
enced study results. Due to the heterogeneity between
study results, no meaningful overall value of mini-
mum clinically important change can be concluded.
Instead, we recommend that MCIDs are considered
context-specific and take account of baseline pain.
The MCID in acute pain is central for the interpretation of
results of randomised trials and meta-analyses and for
determining appropriate sample sizes for new trials, but
it is potentially misguiding if determined, applied or inter-
preted inappropriately. Explicit and conscientious
reflections on the choice of a MCID value are required,
when using it to classify research results as clinically
important or trivial.
Appendix 1
Search strategy
Last search conducted August 2016:
PubMed: (Minimal OR minimally OR minimum OR
“clinically significant” OR “clinically important” OR
“clinically meaningful” OR “clinically relevant” [Title/
Abstract]) AND (Difference OR change OR relief OR re-
duction [Title/Abstract]) AND ((“Pain Measurement*”
OR “Visual Analog Scale”[MeSH Terms]) OR (“numeric
rating scale” [Title/abstract])) AND (Pain [MeSH Terms]
AND pain [Title]) OR ((correlation AND change AND
“visual analog scale” AND “pain relief”[Title]) OR (“mini-
mum clinically significant change” AND pain) OR (“pain
intensity ratings” AND “change scores”) OR (“pain assess-
ment tools” AND “acute pain”) OR (“changes in pain in-
tensity correlate with pain relief”) OR (“minimally
important difference” AND “pain measurement”) OR
(“Minimally important change” AND pain) OR (“mini-
mum clinically important difference” AND pain) OR
(“meaningful change” AND pain [title]) OR (“assessing
change” AND pain [title]) OR (“minimum clinically im-
portant difference” AND “patient-reported outcome”) OR
(“detect changes” AND “pain intensity”)).
Filters: Humans
EMBASE: ((Minimal or minimally or minimum or
clinically significant or clinically important or clinically
meaningful or clinically relevant).ti. or (Minimal or minim-
ally or minimum or clinically significant or clinically im-
portant or clinically meaningful or clinically relevant).ab.
or (Minimal or minimally or minimum or clinically signifi-
cant or clinically important or clinically meaningful or
clinically relevant).kw.) AND ((Difference or change or
relief or reduction).ti. or (Difference or change or relief or
reduction).ab. or (Difference or change or relief or
reduction).kw.) AND ((exp pain assessment/) OR (exp
visual analog scale/) OR (exp rating scale/)) AND exp
pain/dm, dt, ep, th [Disease Management, Drug Therapy,
Epidemiology, Therapy].
Limit to human, Limit to exclude MEDLINE journals
Cochrane Library: (Minimal OR minimally OR mini-
mum OR “clinically significant” OR “clinically important”
OR “clinically meaningful” OR “clinically relevant”:ti,ab,kw
in Cochrane Reviews (Reviews and Protocols), Other
Reviews, Trials and Methods Studies) AND (Difference
OR change OR relief OR reduction:ti,ab,kw in Cochrane
Reviews (Reviews and Protocols), Other Reviews, Trials
and Methods Studies) AND (“Pain Measurement” OR
“Visual Analog Scale” OR “numeric rating scale”:ti,ab,kw
in Cochrane Reviews (Reviews and Protocols), Other Re-
views, Trials and Methods Studies) AND (Pain:ti in
Cochrane Reviews (Reviews and Protocols), Other
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Reviews, Trials and Methods Studies) (Word variations
have been searched).
Appendix 2
Data extraction
Descriptive data
For each study we extracted the following data: Publica-
tion year, study design, setting, type of intervention, sample
size, sex, age and clinical condition of patients, pain level at
baseline, type of pain scale (VAS, NRS or other) and scale
dimensions, type of anchor including wording of the transi-
tion question, concept (e.g. perception of pain relief, overall
status or treatment effect), directionality (one- or two-
sided), number of discriminating subcategories, wording of
items used to obtain minimal clinically important differ-
ence, method of data collection including follow-up time,
number of follow-up measurements per participant,
whether analysis was adjusted for dependency between
measurements and applied method, sampling method (e.g.
consecutive, random or convenience), attrition rate, and
information about any subgroup analysis that had been
undertaken in the studies.
Outcome data
For studies assessing clinically important differences using
the mean difference approach, we extracted the following
outcomes as mean change scores with corresponding
standard error or, if unavailable, other measures of variation
such as standard deviation or 95% confidence interval:
 The minimal clinically important difference for pain
relief (mean absolute and relative change)
 The substantial clinically important difference for
pain relief (mean absolute and relative change)
 The minimal clinically important difference for pain
worsening (mean absolute and relative change)
 The substantial clinically important difference for
pain relief (mean absolute and relative change)
For studies assessing clinically important differences
using the threshold approach, we extracted information
about the definition of responders (patients with relevant
pain relief ) and non-responders and the cut-off point
that differentiated between them with its corresponding
sensitivity and specificity.
Table 5 Relationship between baseline pain and the minimum clinically important differencea
Study Subgroups by baseline
pain, mm
Absolute MCID mm (95% CI) Relative MCID % (95% CI)
Studies assessing MCID stratified by baseline pain
Stahmer [55] ≤50
> 50
NR
NR
25 (SE: 10)b
35 (SE: 6)b
Voepel-Lewis [59] <50
≥ 50
0 (−30 to 20)
20 (13 to 25)
NR
NR
Bird [31] <34
34–66
> 66
11 (7 to 15)
17 (13 to 21)
30 (17 to 43)
NR
NR
NR
Cepeda [33] Moderate (median: 60)
Severe (median: 80)
13 (12 to 14)
18 (17 to 19)
20 (18 to 22)
20 (19 to 22)
Tsze [57] <40
40–69
≥ 70
NR
NR
NR
13 (0 to 29)
16 (10 to 23)
18 (11 to 29)
Tubach [58] Low (mean: 55)
Intermediate (mean: 70)
High (mean: 85)
34 (29 to 38)c
45c
63 (54 to 68)c
NR
NR
NR
Studies assessing correlation between MCID and baseline pain
Barton 2002 (reported in Jensen 2002
[43])
Correlation with baseline
pain
0.48 (P < 0.001) 0.35 (P < 0.01)
Rasmussen 2002 (reported in Jensen
2002 [43])
Correlation with baseline
pain
0.52 (P < 0.001) 0.34 (P < 0.01)
Farrar [36] Correlation with baseline
pain
Patients with higher baseline pain reported
greater relief (e.g. 90 vs. 40 mm, P = 0.048)
No significant differences in degree
of pain relief
aTwo additional studies are not included, since they did not differentiate between pain relief and worsening when assessing the relationship between baseline
pain and MCID (Kelly [46] and Lopez [21])
bPatients answering ‘some’ or ‘partial’ relief
cData is 75th percentile among patients answering ‘a great deal better’ (13) or ‘a good deal better’ (14) on a 15 category scale
MCID minimum clinically important difference, NR not reported, CI confidence interval
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